Beximco Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Iqbal Ahmed

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	39.8yrs
CEO ownership	n/a
Management average tenure	15.5yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO

Iqbal Ahmed

39.8yrs

Tenure

Mr. Iqbal U. Ahmed is MD of Beximco Pharmaceuticals Limited and serves as its Director since 1985. has been a Director of Shinepukur Ceramics Limited since August 24, 2012 and Non-Executive Director at Ban...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Iqbal Ahmed	MD & Director	no data	no data	no data
Mohammad Nawaz	Chief Financial Officer	15.8yrs	no data	no data
S. M. Reza	Chief Operating Officer	15.5yrs	no data	no data
Jamal Choudhury	Director of Accounts & Finance	no data	no data	no data
Rizvi Kabir	Director of Marketing	no data	no data	no data
M. A. Bhuiyan	General Manager of Human Resources	no data	no data	no data
Zakaria Chowdhury	Head of Distribution Services & Director of International Marketing	14.8yrs	no data	no data
Mohammad Ullah	Company Secretary & Executive Director	no data	no data	no data

15.5yrs

Average Tenure

Experienced Management: BXPHARMA's management team is seasoned and experienced (15.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Iqbal Ahmed	MD & Director	39.8yrs	no data	no data
Mohammad Ullah	Company Secretary & Executive Director	no data	no data	no data
Salman Rahman	Vice Chairman	no data	no data	2.04% BDT 724.6m
Abu Bakar Rahman	Director	31.8yrs	no data	no data
Osman Chowdhury	Director	no data	no data	no data
Ahmed Sohail Rahman	Chairman	no data	no data	2.03% BDT 722.9m
Quamrun Ahmed	Non-Executive Director	4yrs	no data	no data
Mamtaz Ahmed	Independent Non-Executive Director	4.3yrs	no data	no data
Reem Shamsuddoha	Non-Executive Director	4yrs	no data	no data
Md. Hosein Khan	Independent Director	3.8yrs	no data	no data

4.2yrs

Average Tenure

64yo

Average Age

Experienced Board: BXPHARMA's board of directors are considered experienced (4.2 years average tenure).

Beximco Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Full year 2024 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024

Dividend of ৳4.00 announced

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 29, 2024

Beximco Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024

Price target increased by 9.3% to ৳168

Third quarter 2024 earnings released: EPS: ৳3.06 (vs ৳2.13 in 3Q 2023)

Beximco Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 29, 2024

Second quarter 2024 earnings released: EPS: ৳3.21 (vs ৳2.77 in 2Q 2023)

Beximco Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director

Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board

Upcoming dividend of ৳3.50 per share at 2.4% yield

Full year 2023 earnings released: EPS: ৳10.34 (vs ৳11.48 in FY 2022)

Beximco Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 05, 2023

Beximco Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023

Beximco Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 19, 2023

Third quarter 2023 earnings released: EPS: ৳2.13 (vs ৳2.47 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ৳2.77 (vs ৳3.84 in 2Q 2022)

Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022

Less than half of directors are independent

Full year 2022 earnings: EPS misses analyst expectations

Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended 30 June 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target increased to ৳182

Less than half of directors are independent

Now 20% undervalued after recent price drop

Consensus EPS estimates increase by 18%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Beximco Pharmaceuticals Limited Launches First Generic Version of Pfizer's COVID-19 Treatment Paxlovid

Upcoming dividend of ৳3.50 per share

Full year 2021 earnings released: EPS ৳11.49 (vs ৳7.88 in FY 2020)

Third quarter 2021 earnings released: EPS ৳3.28 (vs ৳2.02 in 3Q 2020)

Investor sentiment improved over the past week

Beximco Pharmaceuticals Limited Updates on the Supply of Covid-19 Vaccine

Second quarter 2021 earnings released: EPS ৳2.54 (vs ৳1.93 in 2Q 2020)

Analysts increase EPS estimates to ৳10.32

Price target raised to ৳114

Beximco Pharmaceuticals Limited Announces Board Changes

Beximco Pharmaceuticals Limited Provides Update on the Supply of COVID-19 Vaccine

Beximco Pharmaceuticals Limited Confirms Quamrun Naher Ahmed and Reem H. Shamsuddoha as Non-Executive Directors

Investor sentiment improved over the past week

New 90-day high: ৳170

New 90-day high: ৳159

Beximco Pharmaceuticals Limited Announces Directors Appointments

New 90-day high: ৳148

Price target raised to ৳113

New 90-day high: ৳148

Price target raised to ৳116

New 90-day high: ৳145

First quarter 2021 earnings released: EPS ৳2.65

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ৳8.67

Beximco Pharmaceuticals Limited Enters into A Memorandum of Understanding for the Supply and Distribution of 30 Million Doses of the Oxford University/AstraZeneca SARS-CoV-2 Vaccine, AZD1222, in Bangladesh

New 90-day high: ৳127

Beximco Pharmaceuticals Limited Receives US Food and Drug Administration (Fda) Approval for Antiarryhtmic Drug Flecainide

Price target raised to ৳105

New 90-day high - ৳116

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age